Comparison of Plasma Metagenomic Next-generation Sequencing and PCR Methods for Epstein-Barr Virus Viral Load Monitoring in Nasopharyngeal Carcinoma.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2024-12-01 DOI:10.21873/anticanres.17370

Harish N Vasudevan, Ann A Lazar, Kevin Reyes, D A Rong, Shaun Arevalo, Scot Federman, Jason W Chan, Charles Y Chiu, Steve Miller, Sue S Yom

{"title":"Comparison of Plasma Metagenomic Next-generation Sequencing and PCR Methods for Epstein-Barr Virus Viral Load Monitoring in Nasopharyngeal Carcinoma.","authors":"Harish N Vasudevan, Ann A Lazar, Kevin Reyes, D A Rong, Shaun Arevalo, Scot Federman, Jason W Chan, Charles Y Chiu, Steve Miller, Sue S Yom","doi":"10.21873/anticanres.17370","DOIUrl":null,"url":null,"abstract":"Background/aim: Plasma Epstein-Barr virus (EBV) viral load measurement is prognostic in nasopharyngeal carcinoma (NPC) disease monitoring; however, a consensus measurement approach does not exist. This study characterized the clinical performance of metagenomic next-generation sequencing (mNGS), an unbiased sequencing-based assay distinct from polymerase chain reaction (PCR) or targeted sequencing approaches, in 73 peripheral blood specimens from 32 patients diagnosed with NPC.Patients and methods: Samples were analyzed for plasma EBV viral load either by mNGS profiling or PCR-based assays (either LMP2 or BAMHI-W PCR) and compared to tumor presence by clinical assessment. Plasma mNGS-based EBV detection was quantified as reads per million (RPM).Results: Plasma mNGS displayed similar overall performance (100% sensitivity, 86% specificity, 92% accuracy) to BAMHI-W PCR (100% sensitivity, 86% specificity, 94% accuracy) and superior performance to the LMP2 PCR assay (36% sensitivity, 56% specificity, 45% accuracy). In a subset of 13 patients who underwent longitudinal analysis, plasma mNGS EBV RPM correlated with cancer recurrence (95%CI Pre-CRT=232.10±214; 95%CI Post-CRT=0.34±0.32; 95%CI difference=-231.70±214; *p=0.03, paired t-test), suggesting plasma mNGS exhibits potential for monitoring recurrence.Conclusion: Plasma mNGS is a distinct method for EBV titer measurement in NPC patients and more broadly, is a promising method for non-invasive monitoring of disease status for infection-associated malignancies.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5445-5453"},"PeriodicalIF":1.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17370","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Plasma Epstein-Barr virus (EBV) viral load measurement is prognostic in nasopharyngeal carcinoma (NPC) disease monitoring; however, a consensus measurement approach does not exist. This study characterized the clinical performance of metagenomic next-generation sequencing (mNGS), an unbiased sequencing-based assay distinct from polymerase chain reaction (PCR) or targeted sequencing approaches, in 73 peripheral blood specimens from 32 patients diagnosed with NPC.

Patients and methods: Samples were analyzed for plasma EBV viral load either by mNGS profiling or PCR-based assays (either LMP2 or BAMHI-W PCR) and compared to tumor presence by clinical assessment. Plasma mNGS-based EBV detection was quantified as reads per million (RPM).

Results: Plasma mNGS displayed similar overall performance (100% sensitivity, 86% specificity, 92% accuracy) to BAMHI-W PCR (100% sensitivity, 86% specificity, 94% accuracy) and superior performance to the LMP2 PCR assay (36% sensitivity, 56% specificity, 45% accuracy). In a subset of 13 patients who underwent longitudinal analysis, plasma mNGS EBV RPM correlated with cancer recurrence (95%CI Pre-CRT=232.10±214; 95%CI Post-CRT=0.34±0.32; 95%CI difference=-231.70±214; *p=0.03, paired t-test), suggesting plasma mNGS exhibits potential for monitoring recurrence.

Conclusion: Plasma mNGS is a distinct method for EBV titer measurement in NPC patients and more broadly, is a promising method for non-invasive monitoring of disease status for infection-associated malignancies.

查看原文本刊更多论文

新一代血浆宏基因组测序与PCR检测鼻咽癌eb病毒载量的比较

背景/目的：血浆eb病毒（EBV）载量测定在鼻咽癌（NPC）疾病监测中的预后价值；然而，共识度量方法并不存在。本研究对32例鼻鼻癌患者的73份外周血标本进行了宏基因组新一代测序（mNGS）的临床表现。mNGS是一种基于无偏倚测序的检测方法，不同于聚合酶链反应（PCR）或靶向测序方法。患者和方法：通过mNGS分析或基于PCR的检测（LMP2或BAMHI-W PCR）分析样本的血浆EBV病毒载量，并通过临床评估与肿瘤存在情况进行比较。基于mngs的血浆EBV检测被量化为每百万读取（RPM）。结果：血浆mNGS与BAMHI-W PCR（100%灵敏度，86%特异性，94%准确性）具有相似的总体性能（100%灵敏度，86%特异性，92%准确性），优于LMP2 PCR（36%灵敏度，56%特异性，45%准确性）。在13例接受纵向分析的患者亚组中，血浆mNGS EBV RPM与癌症复发相关(95%CI =232.10±214；95%可信区间Post-CRT = 0.34±0.32;95%可信区间差异= -231.70±214;*p=0.03，配对t检验)，提示血浆mNGS具有监测复发的潜力。结论：血浆mNGS是鼻咽癌患者EBV滴度测定的独特方法，更广泛地说，是一种有前途的无创监测感染相关恶性肿瘤疾病状态的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.